| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) through any online brokerage.
Other companies in Aurinia Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Aurinia Pharmaceuticals has a consensus price target of $15.50.
The stock price for Aurinia Pharmaceuticals (NASDAQ: AUPH) is $15.515 last updated October 6, 2026 at 7:08 PM EDT.
There are no upcoming dividends for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
